Donation

Myeloma Minute: Adjusting to the New Normal

myelomaMinBanner4.15.2020.jpg

| INNOVATION | Latest Research

540x270NewNormal.jpg

The Transition to the New Normal Will Take Time

As more data about COVID-19 pour in from around the world, a picture of the new coronavirus’s impact on our future is beginning to take shape. Three elements are vital in our transition to the new normal, says IMF Chairman Dr. Brian G.M. Durie: Testing, Tracing, and Treatments.

ReadBlogButton.png

| INNOVATION | COVID-19 Research

540x270CovidResearch.jpg

World-leading Plasma Companies Join Together to Develop Potential Hyperimmune Immunoglobulin to Work Against COVID-19

A global alliance between leading plasma companies has been formed to “develop a potential plasma-derived therapy for treating COVID-19. The alliance will begin immediately with the investigational development of one, unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin medicine with the potential to treat individuals with serious complications from COVID-19.”

LearnMoreButton.png

| INSPIRATION | Virtual Race

540x270runningwdog.jpg

Schedule a Private Run/Walk from Any Location for This Year’s Miles for Myeloma!

The Miles for Myeloma 5K Run/Walk is NOW VIRTUAL! The race usually takes place in Philadelphia, but now anyone anywhere in the world can participate! Visit the link below to learn about this new and exciting style of racing.

LearnMoreButton.png

| INSPIRATION | Vacation Getaway

250x250hawaii.jpg

| EDUCATION | Publication

250x250USarclisa.jpg

And This Too Shall Pass….
IMF Publishes New Booklet on Sarclisa (isatuximab-irfc)

Once again, the IMF is hosting a raffle for a 10-day stay at the Villa Ono Oasis in historic Kailua-Kona, Hawaii. While many of us have been affected by COVID-19, we hope to remind you that this too shall pass. If you purchase the winning $50 raffle ticket, you could find yourself sipping a tropical beverage next to a private pool, just minutes from the Hawaiian coastline.

The IMF’s new Understanding SARCLISA® (isatuximab-irfc) booklet focuses on a novel anti-CD38 monoclonal antibody that is FDA-approved for patients with relapsed and refractory myeloma. Sarclisa binds to myeloma cells to kill them directly, and recruits other immune system cells to kill myeloma cells as well.

LearnMoreButton.png

DownloadButton.png

| ACTION | Advocacy Alert

540x270Gavelscope.jpg

Take Action-Support the Cancer Drug Parity During COVID-19

Cancer patients are facing unique challenges during the COVID-19 pandemic, and the IMF’s Advocacy team has been working hard to address these issues with lawmakers.

When medically appropriate, some patients are being transitioned onto orally administered cancer medications to ensure they have the ability to stay safely at home. Patients must currently pay significantly more out-of-pocket for these drugs due to the way insurers cover them. While the IMF has been pushing for the passage of H.R. 1730/S. 741, the Cancer Drug Parity Act prior to the COVID-19 pandemic, this issue is now more important than ever.

IMF’s Advocacy team led efforts to inform legislators about how the Cancer Drug Parity Act will help patients during the COVID-10 pandemic. You can view an example of these letters to Congress HERE. We need your help though! Let your Senators and Representatives know you support the passage of the Cancer Drug Parity Act by clicking the button below.

TakeActionButton.png

| INNOVATION | Research Grants

540x270_BNDResearchgrant.jpg

Calling All Researchers: Submit Your Grant Applications

The Brian D. Novis Research Grants honor the IMF’s founder Brian Novis, who succumbed to multiple myeloma in July of 1992. The grants are awarded to researchers working in the field of multiple myeloma and related disorders, including smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), and immunoglobulin-derived amyloidosis. The 2020 grants will support senior research projects with $80,000 each and junior research projects with $50,000 each. The deadline to receive the applications is Saturday, August 1, 2020.

LearnMoreButton.png

| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series

DurieVideoBox4.16.2020.png

CLINICAL TRIALS
EVENTS

Search the Myeloma Matrix 2.0

Join the conversation about myeloma on the Smart Patients Message Board

Clinical Trial Fact Sheets

OCEAN Trial (Now Accruing)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)

Ongoing
Hawaiian Vacation Raffle
Kailua-Kona, Hawaii

Ongoing
Hatfield Hike
Appalachian Trail

April 25, 2020
VIRTUAL Miles for Myeloma 5K Run/Walk
Nationwide

subscribe_button.png     donate_button_bottom.png
We Thank Our Sponsors:
Amgen, Bristol-Myers Squibb, Genentech, GSK, Sanofi-Genzyme, and Takeda Oncology

We also thank individuals like you for your continued support!

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.